GlassScriptPhysician profile
Suzanne R Rosen
NPI 1346224466
$6,537.58
in general payments reported to CMS, 2019-2025
39 companies · $855 in 2025
The $855 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $789 · 2020: $353 · 2021: $907 · 2022: $1,179 · 2023: $1,424 · 2024: $1,030 · 2025: $855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,309.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,927.34 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $587.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $572.34 | 2019-2025 | |
| Abbott Laboratories | $447.89 | 2022-2023 | Freestyle Libre 3 |
| Lilly USA, LLC | $390.82 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $384.47 | 2019-2020 | |
| Amgen INC. | $382.93 | 2019-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $325.82 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $277.29 | 2019-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $135.78 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $127.13 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $116.75 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $110.90 | 2021 | |
| Dexcom, INC. | $90.64 | 2022-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.65 | 2019-2023 | Jardiance |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Rosen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.